OPTHEA - Sponsored by OptheaActive Study | Duration: 24 weeks
Opthea is a phase 2B, multicenter, randomized, masked, controlled, dose ranging trial to study the safety and efficacy of intravitreal OPT-302 in combination with Lucentis, compared with Lucentis alone, in participants with neovascular age-related macular degeneration (wet AMD). All patients in the study receive Lucentis, supplied by the sponsor. There will be three groups of patients, randomized at a 1:1:1 ratio. Group 1 receives the higher-dose OPT-302 with Lucentis; Group 2 receives the lower-dose OPT-302 with Lucentis. Group 3 is a control group and will receive Lucentis monotherapy. This study plans to enroll 351 patients. Trial participation is 6 months.